<DOC>
	<DOCNO>NCT01931956</DOCNO>
	<brief_summary>Prospective , multicenter , continue access registry MitraClip® Cardiovascular Valve Repair System treatment mitral valve regurgitation . Clinical follow-up discharge , 30 day , 6 month , 12 month , 2- , 3- , 4- , 5-years . The study consist two arm : high risk group non-high risk group . Enrollment high risk arm ongoing . Enrollment non-high risk arm conclude April 2011 .</brief_summary>
	<brief_title>Real World Expanded Multicenter Study MitraClip® System ( REALISM )</brief_title>
	<detailed_description>The EVEREST II REALISM study ( REALISM study ) continue access registry design continue data collection use Abbott Vascular 's MitraClip System ( MitraClip® Device ) `` real world '' condition . After completion enrollment pivotal EVEREST II Randomized Controlled Trial ( RCT ) EVEREST II High Risk Registry Study , continue access technology warrant collect additional safety effectiveness data MitraClip® Device . This continue access study approve FDA November 21 , 2008 ( G030064 ) . There two arm ( High Risk Non-High Risk ) REALISM study . Enrollment Non-High Risk arm study conclude April 14 , 2011 enrollment High Risk arm conclude December 19 , 2013 . REALISM prospective , multi-center , study safety effectiveness endovascular approach treatment mitral valve regurgitation use Evalve Cardiovascular Valve Repair System ( MitraClip® implant ) . Patients moderate-to-severe ( 3+ ) severe ( 4+ ) mitral regurgitation ( MR ) , determine site transthoracic echocardiogram ( TTE ) , consider enrollment study . The TTE transesophageal echocardiogram ( TEE ) use assess eligibility criterion MR severity , valve anatomy leave ventricular parameter .</detailed_description>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Patients screen EVEREST II REALISM Study first screen high risk ( HR ) status enrol HR arm meet eligibility arm study . If meet eligibility HR arm , patient screen eligibility enrollment nonhigh risk ( NHR ) arm EVEREST II REALISM . Key Inclusion Criteria Moderate severe ( 3+ ) severe ( 4+ ) chronic mitral valve ( MV ) regurgitation : 1 . Symptomatic &gt; 25 % LVEF LVESD ≤55mm , 2 . Asymptomatic one following : i. LVEF 25 % 60 % ii . LVESD ≥40 mm iii . New onset AFib iv . PASP &gt; 50mmHg rest &gt; 60mmHg exercise . Candidate MV surgery . The primary regurgitant jet originate malcoaptation A2 P2 scallop MV . Transseptal catheterization determine feasible treat physician . High Risk Inclusion Criteria ( High Risk Arm ) Predicted procedural mortality risk calculate use STS surgical risk calculator ≥ 12 % , judgment cardiac surgeon , patient consider high risk surgical candidate due presence one follow indication : 1 . Porcelain aorta mobile ascend aortic atheroma 2 . Postradiation mediastinum 3 . Previous mediastinitis 4 . Functional MR EF &lt; 40 5 . Over 75 year old EF &lt; 40 6 . Reoperation patent graft 7 . Two prior chest surgery 8 . Hepatic cirrhosis 9 . Three ( 3 ) follow STS high risk factor 9.1 Creatinine &gt; 2.5 mg/dL 9.2 Prior chest surgery 9.3 Age 75 9.4 EF &lt; 35 Key Exclusion Criteria Evidence AMI prior 12 week intend treatment . The need cardiac surgery . Any endovascular therapeutic interventional surgical procedure perform within 30 day prior index procedure . In judgment Investigator , femoral vein accommodate 24F catheter presence inferior vena cava ( IVC ) filter would interfere advancement catheter ipsilateral DVT present . Severe LV dysfunction ( EF &lt; 25 % and/or LVESD &gt; 55mm ) . MV orifice area &lt; 4.0 cm2 . If leaflet flail present : 1 . Flail Width ≥15 mm , 2 . Flail Gap ≥10 mm . If leaflet tether present : 1 . Vertical coaptation length &lt; 2 mm . Severe mitral annular calcification . Leaflet anatomy may preclude clip implantation , proper clip position leaflet sufficient reduction MR . This may include : 1 . Evidence calcification grasp area A2 and/or P2 scallop 2 . Presence significant cleft A2 P2 scallop 3 . More one anatomic criterion dimensionally near exclusion limit 4 . Bileaflet flail severe bileaflet prolapse 5 . Lack primary secondary chordal support Hemodynamic instability ( systolic pressure &lt; 90 mmHg without afterload reduction cardiogenic shock need inotropic support intraaortic balloon pump ) . Need emergency surgery reason . Prior MV surgery valvuloplasty currently implant mechanical prosthetic valve currently implant VAD . Systolic anterior motion MV leaflet . Hypertrophic cardiomyopathy . Echocardiographic evidence intracardiac mass , thrombus vegetation . History stroke document TIA within prior 6 month . Upper GI bleeding within prior 6 month . History bleed diathesis coagulopathy subject refuse blood transfusion . Life expectancy &lt; 12 month . Platelet count &lt; 75,000 cells/mm³ . Creatinine &gt; 2.5mg/dL ) Active infection require current antibiotic therapy . Patients transesophageal echocardiography ( TEE ) contraindicate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Mitral Valve Insufficiency</keyword>
	<keyword>Mitral Valve Regurgitation</keyword>
	<keyword>Mitral Valve Incompetence</keyword>
	<keyword>Mitral Regurgitation</keyword>
	<keyword>Mitral Insufficiency</keyword>
	<keyword>Mitral Valve</keyword>
	<keyword>MR</keyword>
	<keyword>Mitral Valve Prolapse</keyword>
	<keyword>E2E - Edge Edge</keyword>
	<keyword>Alfieri Technique</keyword>
	<keyword>MitraClip</keyword>
	<keyword>Functional MR</keyword>
	<keyword>Degenerative MR</keyword>
	<keyword>Echocardiogram</keyword>
	<keyword>CAD - Coronary Artery Disease</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Heart Attack</keyword>
	<keyword>EVEREST</keyword>
	<keyword>EVEREST I</keyword>
	<keyword>EVEREST II</keyword>
	<keyword>REALISM</keyword>
</DOC>